Steven D. Vold

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Role not yet determined Is this you? Add your title

University of Arkansas primary UAMS

Also affiliated: Northwestern University (1997–1998); University of North Texas (2020); Novartis (Switzerland) (2025); Carl Zeiss (Germany) (2025); RAND Corporation (2024); United States Food and Drug Administration (2024); Center for Devices and Radiological Health (2024); Thomas Jefferson University (2024); University of California, Los Angeles (2024); University of North Texas Health Science Center (2020); The University of Texas at San Antonio Health Science Center (2020); Texas A&M University System (2002–2008); Regeneron (United States) (2025); Volda University College (2016); New York Eye and Ear Infirmary (2020); Columbia University Irving Medical Center (2020); Temple College (2000–2008); Nassau University Medical Center (2020); Laredo Community College (2020); AbbVie (United States) (2025); Allergan (Ireland) (2025); Mercy Hospital Springfield (2020); Aerie Pharmaceuticals (United States) (2025); Sightsavers (2020); Control Vision (United States) (2013–2023); Johnson & Johnson (Germany) (2025); Creative Commons (2020); Williamson College (2020); Dean McGee Eye Institute (2014); Immunomedics (United States) (2020); Scott & White Memorial Hospital (2000–2008); Medical Prescription Services (2000); ATUM (United States) (2020); Allergan (United States) (2025); ZeptoMetrix (United States) (2011); Dermatology Specialists (2020); Ophthalmology Associates (United States) (2020); Université de Montréal (2020); Alcon (China) (2012); Rogers (United States) (2008–2010); University of Oklahoma (2014); Wills Eye Hospital (2024); Stanford University (2024)

Formerly Arkansas Affiliated with UAMS through 2020.

25 h-index 64 pubs 2,446 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Steven D. Vold's research focuses on the surgical treatment of glaucoma, particularly primary open-angle glaucoma. His work has investigated various minimally invasive glaucoma surgeries (MIGS) and traditional surgical approaches, comparing their safety, effectiveness, and cost. He has published extensively on the use of micro-stents, including the CyPass Supraciliary Micro-Stent, and compared these to established procedures like trabeculectomy.

Vold has been involved in prospective, randomized, controlled trials evaluating novel implants for intraocular pressure reduction in patients with glaucoma and cataracts. His publications include results from pivotal trials and long-term follow-up studies, such as the COMPASS XT study. He has also examined the cost-effectiveness of glaucoma medications, contributing to a broader understanding of glaucoma management strategies.

With a career marked by frequent publications and a significant citation count, Vold is recognized as a highly cited researcher. His scholarly output includes 64 publications, accumulating over 2,446 citations, and he holds an h-index of 25. His recent activity indicates continued engagement in research within ophthalmology.

Metrics

h-index: 25
Publications: 64
Citations: 2,446

Selected Publications

One-Year Real-World Outcomes of Ab-Externo Gel Stent Placement From the EXPAND Study (2025)

Journal of Glaucoma 1 citation DOI OpenAlex
Twelve-month outcomes of an ab interno gelatin stent combined with cataract surgery or as a standalone procedure in pseudophakic eyes with open-angle glaucoma (2020)

Journal of Cataract & Refractive Surgery 7 citations DOI OpenAlex
Prioritizing Outcome Preferences in Patients with Ocular Hypertension and Open-Angle Glaucoma Using Best–Worst Scaling (2019)

Ophthalmology Glaucoma 15 citations DOI OpenAlex